The pathogenesis of inflammatory bowel disease (IBD) involves complex molecular mechanisms, and achieving clinical remission remains challenging. This study aims to identify IBD-potential biomarkers, analyze their correlation with immune cell infiltration, and identify genes that have a causal relationship with IBD. RNA-seq datasets for IBD were retrieved from GEO, stratified into discovery (GSE75214), validation (GSE36807), and independent testing cohorts (GSE179285, GSE47908). Through comparative expression profiling of the discovery cohort, IBD-associated differentially expressed genes (DEGs) were detected. Core candidate genes were subsequently prioritized using protein-protein interaction network analysis, further refined through machine learning approaches (Random Forest/Support Vector Machines). Immune cell abundance quantification and statistical correlation analyses with IBD-associated transcripts were conducted via the CIBERSORTx deconvolution algorithm. To complement these findings, blood expression quantitative trait loci (eQTL) data from GTExv8.ALL.Whole_Blood were integrated with IBD genome-wide association statistics from the FinnGen consortium. This multi-omics integration framework employed: (1) Bayesian colocalization to assess shared causal variants, (2) HEIDI heterogeneity testing, and (3) summary Mendelian randomization (SMR) for causal inference validation. Three genes, IRF1, GBP5, and PARP9, demonstrated significant IBD-promoting effects. The characteristic biomarkers of IBD were associated with immune cell infiltration. SMR analysis based on eQTL data showed that IRF1 was significantly associated with the risk of IBD. Moreover, IRF1 passed the HEIDI test of > 0.05 on gene expression, and IRF1 demonstrated the ability to promote the development of IBD. This integrative analysis identifies IRF1, GBP5, and PARP9 as potential genes associated with IBD pathogenesis. SMR analysis based on eQTL data revealed that IRF1 was significantly associated with the risk of IBD. The relationship between IRF1 and IBD risk highlights its potential as both a therapeutic target and diagnostic biomarker.
Myelosuppression is a major adverse effect of 5-fluorouracil (5-FU) chemotherapy. However, recent findings indicate that 5-FU selectively suppresses myeloid-derived suppressor cells (MDSCs), to enhance antitumor immunity in tumor-bearing mice. 5-FU-mediated myelosuppression may thus have a beneficial effect for cancer patients. The molecular mechanism underlying 5-FU’s suppression of MDSCs is currently unknown. We aimed at testing the hypothesis that 5-FU suppresses MDSCs through enhancing MDSC sensitivity to Fas-mediated apoptosis. We observed that, although FasL is highly expressed in T cells, Fas is weakly expressed in myeloid cells in human colon carcinoma, indicating that downregulation of Fas is a mechanism underlying myeloid cell survival and accumulation in human colon cancer. 5-FU treatment upregulated expression of both p53 and Fas, and knocking down p53 diminished 5-FU-induced Fas expression in MDSC-like cells, in vitro. 5-FU treatment also increased MDSC-like cell sensitivity to FasL-induced apoptosis in vitro. Furthermore, we determined that 5-FU therapy increased expression of Fas on MDSCs, suppressed MDSC accumulation, and increased CTL tumor infiltration in colon tumor-bearing mice. In human colorectal cancer patients, 5-FU chemotherapy decreased MDSC accumulation and increased CTL level. Our findings determine that 5-FU chemotherapy activates the p53-Fas pathway, to suppress MDSC accumulation, to increase CTL tumor infiltration.
Background: This study aimed to develop an artificial intelligence predictive model for predicting the probability of developing BM in CRC patients.Methods: From SEER database, 50,566 CRC patients were identified between January 2015 and December 2019 without missing data. SVM and LR models were trained and tested on the dataset. Accuracy, area under the curve (AUC), and IDI were used to evaluate and compare the models.Results: For bone metastases in the entire cohort, SVM model with poly as kernel function presents the best performance, whose accuracy is 0.908, recall is 0.838, and AUC is 0.926, outperforming LR model. The top three most important factors affecting the model's prediction of BM include extraosseous metastases (EM), CEA, and size.Conclusion: Our study developed an SVM model with poly as kernel function for predicting BM in CRC patients. SVM model could improve personalized clinical decision-making, help rationalize the bone metastasis screening process, and reduce the burden on healthcare systems and patients.
Cholera, a severe diarrhoeal illness caused by Vibrio cholerae (V. cholerae), poses a significant threat to public health worldwide. The emergence of multidrug-resistant V. cholerae strains underscores the urgent need for preventive and therapeutic interventions. In this study, we elucidate the role of outer membrane protein V (OmpV) in the virulence of V. cholerae and propose a therapeutic strategy targeting OmpV. Subcellular localization analysis shows that OmpV is present in both the bacterial outer membrane (OM) and bacterial extracellular vesicles (BEVs). When V. cholerae enters the small intestine, OmpV is activated by the CarSR two-component system in response to cationic antimicrobial peptides (CAMPs) in the small intestine, leading to increased bacterial pathogenicity. The upregulation of ompV not only augments bacterial adhesion but also promotes the internalization of BEVs into host cells, thereby increasing the delivery of cholera toxin (CT) to host cells. Computational aided drug design (CADD) shows that the small-molecule inhibitor C607-0736 is capable of disrupting the virulence functions of OmpV. Animal experiments show that C607-0736 efficiently inhibits the colonization and pathogenicity of the V. cholerae O1 and O139 strains. These findings underscore the therapeutic potential of OmpV-targeting strategies and offer promising avenues for addressing multidrug-resistant V. cholerae.